Your browser doesn't support javascript.
loading
Chronic Recurrent Multifocal Osteomyelitis: A Comprehensive Literature Review.
Hassan, Mariam; Assi, Heabah; Hassan, Maha; Bies, Jared J; Prakash, Swathi; Hassan, Ali; Alhariri, Sara; Dihowm, Fatma.
Afiliación
  • Hassan M; Internal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
  • Assi H; Internal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
  • Hassan M; Biomedical Sciences, Gulf Medical University, Ajman, ARE.
  • Bies JJ; Internal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
  • Prakash S; Internal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
  • Hassan A; Emergency Medicine, Mercy Health St. Elizabeth Boardman Hospital, Boardman, USA.
  • Alhariri S; Internal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
  • Dihowm F; Internal Medicine, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, USA.
Cureus ; 15(8): e43118, 2023 Aug.
Article en En | MEDLINE | ID: mdl-37692753
Chronic recurrent multifocal osteomyelitis (CRMO) is a non-infectious, inflammatory disorder of the bones. CRMO typically affects children, with a predisposition to females. Bone-related pain is often felt in the metaphysis of long bones, particularly of the lower extremities, but it can also target other sites at varied time intervals. Patients are likely to complain of tenderness and swelling that may cause considerable disability and adversely impact quality of life. There are three main pathophysiological mechanisms that have been hypothesized to drive CRMO including imbalanced cytokine expression, increased inflammasome activation, and enhanced osteoclast differentiation. Therapies have been based on targeting and suppressing these key players in CRMO patients. The first step in management involves pain control. Non-steroidal anti-inflammatory drugs should provide initial relief, albeit temporarily. It is imperative to initiate immunosuppressive medication that will help limit bone involvement and thereby prevent the development of fractures or leg-length discrepancies, for example. The purpose of this literature review is to study the pathophysiology of CRMO and carefully dissect the agents that have been previously employed in the management of CRMO patients. This could allow for the purposeful formulation of individualized care plans and improving the overall well-being of patients. The authors included a multitude of PubMed-indexed articles published from 2000 onwards in this review.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Aspecto: Patient_preference Idioma: En Revista: Cureus Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Aspecto: Patient_preference Idioma: En Revista: Cureus Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos